|
NSJ Bioreagents
cd13 antibody / anpep Cd13 Antibody / Anpep, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cd13 antibody / anpep/product/NSJ Bioreagents Average 99 stars, based on 1 article reviews
cd13 antibody / anpep - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
Vector Laboratories
dl 1174 pericytes goat anti cd13 Dl 1174 Pericytes Goat Anti Cd13, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dl 1174 pericytes goat anti cd13/product/Vector Laboratories Average 96 stars, based on 1 article reviews
dl 1174 pericytes goat anti cd13 - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
R&D Systems
cd13 Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cd13/product/R&D Systems Average 96 stars, based on 1 article reviews
cd13 - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
R&D Systems
r d systems ab 2227288 anti actin R D Systems Ab 2227288 Anti Actin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/r d systems ab 2227288 anti actin/product/R&D Systems Average 96 stars, based on 1 article reviews
r d systems ab 2227288 anti actin - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
R&D Systems
pericyte marker cd13 Pericyte Marker Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/pericyte marker cd13/product/R&D Systems Average 96 stars, based on 1 article reviews
pericyte marker cd13 - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
R&D Systems
anti goat cd13 ![]() Anti Goat Cd13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti goat cd13/product/R&D Systems Average 96 stars, based on 1 article reviews
anti goat cd13 - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
R&D Systems
af2335 donkey anti goat 568 ![]() Af2335 Donkey Anti Goat 568, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/af2335 donkey anti goat 568/product/R&D Systems Average 96 stars, based on 1 article reviews
af2335 donkey anti goat 568 - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
Proteintech
1 ap ![]() 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/1 ap/product/Proteintech Average 93 stars, based on 1 article reviews
1 ap - by Bioz Stars,
2026-06
93/100 stars
|
Buy from Supplier |
Journal: bioRxiv
Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice
doi: 10.64898/2026.02.28.708735
Figure Lengend Snippet: a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, Cd13-positive immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.
Article Snippet: The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500);
Techniques: Comparison
Journal: bioRxiv
Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice
doi: 10.64898/2026.02.28.708735
Figure Lengend Snippet: a. Mean Open field (OF) locomotion scores for the saline and coacervate treated SCI mice over two weeks. **p value < 0.005, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test. b. Grid walk (GW) test performance for the saline and coacervate treated SCI mice over two weeks, **p value < 0.0001, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. c. Correlation analysis of OF and GW scores for carrier injected SCI mice, with the behavioral tests showing strong positive correlation (r=0.86), p-value <0.0001, t-test for Pearson’s linear correlation. d. Pie charts indicating the AFS subgroup distribution across the saline and coacervate injected SCI mice. e. Mean OF, GW and combined assessment PMP values for the AFS designation separated by carrier injection type. f. Confusion matrix showing the percentage of mice displaying Class 1, 2 and 3 type recovery from the three AFS subgroups based on the combined evaluation of OF and GW testing results. g. Representative survey IHC images of carrier treated SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes and Cd13-positive immune and stromal cells. h. Quantification of SCI lesion size at 14 days after SCI stratified by subgroup and carrier injection. *p value < 0.05, Two-way ANOVA with Tukey multiple comparison test. i. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup and carrier injection., *p value < 0.02, Two-way ANOVA with Tukey multiple comparison test.
Article Snippet: The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500);
Techniques: Saline, Comparison, Injection